Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

Showing the 40 largest recruiting trials by target enrollment in Mississippi. Use the search field to focus on a condition or drug.

Recruiting 80,000 participants

Generic Database of Very Low Birth Weight Infants

NICHD Neonatal Research Network

NCT00063063

Recruiting 68,000 participants

Follow-up Visit of High Risk Infants

NICHD Neonatal Research Network

NCT00009633

Recruiting 20,000 participants

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

Freenome Holdings

NCT06122077

Recruiting Phase 4 10,742 participants

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Ohio State University

NCT06468202

Recruiting 8,000 participants

Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY

Massachusetts General Hospital

NCT04916210

Recruiting Phase 3 5,200 participants

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Colorado Prevention Center

NCT06008197

Recruiting Phase 3 4,390 participants

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Merck Sharp & Dohme

NCT07044297

Recruiting 4,000 participants

EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

Natera

NCT06808880

Recruiting Phase 3 4,000 participants

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Vaxcyte

NCT07284654

Recruiting 3,291 participants

Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae

Duke University

NCT06815536

Recruiting 3,110 participants

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Mayo Clinic

NCT05051722

Recruiting 3,000 participants

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Duke University

NCT01915511

Recruiting NA 1,605 participants

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

Concept Medical

NCT06271590

Recruiting Phase 3 1,216 participants

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Bristol-Myers Squibb

NCT05827016

Recruiting Phase 3 1,200 participants

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT

Major Extremity Trauma Research Consortium

NCT04678154

Recruiting Phase 4 1,094 participants

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

ModernaTX

NCT06585241

Recruiting Phase 3 1,000 participants

Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial

Major Extremity Trauma Research Consortium

NCT07006675

Recruiting Phase 3 1,000 participants

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Bristol-Myers Squibb

NCT06561386

Recruiting Phase 3 1,000 participants

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

Philip Spinella

NCT06070350

Recruiting Phase 3 970 participants

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Direct Biologics

NCT05354141

Recruiting Phase 4 832 participants

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

ModernaTX

NCT07089706

Recruiting Phase 3 822 participants

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Regeneron Pharmaceuticals

NCT06091254

Recruiting Phase 3 770 participants

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Merck Sharp & Dohme

NCT06824467

Recruiting 760 participants

Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)

Zimmer Biomet

NCT05787821

Recruiting Phase 4 700 participants

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Novartis Pharmaceuticals

NCT05803941

Recruiting Phase 3 621 participants

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

BioNTech SE

NCT06712355

Recruiting Phase 3 614 participants

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Merck Sharp & Dohme

NCT06170788

Recruiting Phase 3 586 participants

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Bristol-Myers Squibb

NCT06976203

Recruiting NA 584 participants

Zimmer Biomet Shoulder Arthroplasty PMCF

Zimmer Biomet

NCT04984291

Recruiting Phase 3 556 participants

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Merck Sharp & Dohme

NCT06074588

Recruiting Phase 3 528 participants

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Melt Pharmaceuticals

NCT06383273

Recruiting NA 500 participants

Mississippi Delta Community Care Home Visits Program

Jackson State University

NCT07006324

Recruiting NA 500 participants

Encore PFO Closure Device - The PerFOrm Trial

Encore Medical

NCT05537753

Recruiting NA 500 participants

Cord Clamping Among Neonates With Congenital Heart Disease

Carl Backes, MD

NCT06153459

Recruiting NA 492 participants

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

Concept Medical

NCT05908331

Recruiting NA 486 participants

Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial

University of Alabama at Birmingham

NCT06420531

Recruiting Phase 3 470 participants

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Regeneron Pharmaceuticals

NCT06149286

Recruiting Phase 3 460 participants

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

AbbVie

NCT06614192

Recruiting Phase 3 454 participants

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Biogen

NCT06935357

Recruiting Phase 3 450 participants

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

AbbVie

NCT05711394

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →